Morphogenics & Antibody Drug Conjugate Technology


Antibody Technology

Morphogenics is a broad-based, proprietary, platform technology that regulates the ability of a host organism to repair mutations that occur during DNA replication. All proliferating cells duplicate their genetic material prior to dividing into two siblings (sibs).
Read More

Antibody-Drug Conjugate (ADC) Technology

The random conjugation of toxins, dyes, peptides, or other payloads to monoclonal antibodies often targets free thiol groups generated by partial reduction methods or lysine residues using succinimide- or isothiocyanate-based chemistry. There remains a need for conjugation technologies targeting specific amino acid residues as a way to produce a homogeneous antibody-drug conjugate (ADC) product with a defined drug-to-antibody ratio (DAR).
Read More